BioXcel Therapeutics (BTAI) Equity Ratio (2022 - 2025)
Historic Equity Ratio for BioXcel Therapeutics (BTAI) over the last 4 years, with Q3 2025 value amounting to 1.99.
- BioXcel Therapeutics' Equity Ratio fell 1334.2% to 1.99 in Q3 2025 from the same period last year, while for Sep 2025 it was 1.99, marking a year-over-year decrease of 1334.2%. This contributed to the annual value of 2.43 for FY2024, which is 21673.37% down from last year.
- Per BioXcel Therapeutics' latest filing, its Equity Ratio stood at 1.99 for Q3 2025, which was down 1334.2% from 4.17 recorded in Q2 2025.
- BioXcel Therapeutics' Equity Ratio's 5-year high stood at 0.92 during Q1 2022, with a 5-year trough of 4.17 in Q2 2025.
- In the last 4 years, BioXcel Therapeutics' Equity Ratio had a median value of 0.77 in 2023 and averaged 0.87.
- Per our database at Business Quant, BioXcel Therapeutics' Equity Ratio tumbled by 281281.03% in 2024 and then plummeted by 1334.2% in 2025.
- Quarter analysis of 4 years shows BioXcel Therapeutics' Equity Ratio stood at 0.37 in 2022, then tumbled by 305.57% to 0.77 in 2023, then plummeted by 216.73% to 2.43 in 2024, then increased by 18.25% to 1.99 in 2025.
- Its last three reported values are 1.99 in Q3 2025, 4.17 for Q2 2025, and 2.34 during Q1 2025.